Overview

PSMA and C-11 Choline PET in Patients With Biochemical Recurrence of Prostate Cancer

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Imaging and staging of prostate cancer is critical for surgical and treatment planning. In this protocol we will image patients with suspected metastatic prostate cancer using 11C-Choline PET and Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or F-18 labeled PSMA 1007 in order to demonstrate their utility in detecting prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Choline